A 44-year-old man with splenectomised refractory autoimmune thrombocytopenic purpura (AITP) of 10 years' duration underwent an autologous, T cell-depleted marrow transplant following conditioning with thiotepa and CY. There was no response to the transplant procedure. This is the fourth case in the literature to show failure following autologous stem cell transplantation, although complete, steroid-independent remissions were obtained in the first two patients for over 1 year.
Refractory autoimmune idiopathic thrombocytopenic purpura (AITP) is defined as no response to, or relapse after splenectomy, unresponsiveness to corticosteroids at standard doses, and need for further treatment because of recurrent haemorrhagic symptoms and/or unsafe platelet levels. 1, 2 This subgroup of AITP may represent 25-30% of all cases, and besides suffering significant morbidity, is associated with a mortality of 16% because of the combined effects of disease and treatment. Four 'levels of therapy' have been recently defined by McMillan, 2 but none may be successful in markedly refractory patients.
Stem cell therapy following peak, dose-intensive immunosuppressive regimens is currently being explored for severe autoimmune diseases (SADs). 3 The consensus has been reached that autologous SC transplantation, from marrow, blood or the combination of both, is safer and ethically more acceptable than the allogeneic procedure, 4 even if immunologically less promising for many reasons discussed in detail elsewhere. 3 It is suggested that T cell depletion (TCD) might be useful to reduce the reinfusion of autoreactive T lymphocytes. obtained, 5 but unfortunately both patients have subsequently relapsed after 12 and 18 months, respectively. One of them underwent a second autologous transplant and subsequently died (Lim SH, personal communication). Failure following autotransplantation in another case has also been reported recently. 6 We report yet another patient with AITP who did not obtain remission following an autologous, T cell-depleted marrow transplant.
Case report
A 44-year-old man developed severe AITP in 1988. Platelet-specific antibodies were demonstrated initially, but not consistently. A series of bone marrow aspirates performed during these 10 years were consistently compatible with the diagnosis. He was a poor responder to corticosteroids, but had a peak of 700 ϫ 10 9 /l platelets following splenectomy. He relapsed after 3 months, had recurrent severe mucosal and intestinal haemorrhages, and was treated between 1991 and 1997 with high-dose IgG and various immunosuppressants, including bolus intravenous cyclophosphamide (CY) to a total of 3 g. Platelet responses were scarce (never over 30 ϫ 10 9 /l) and short-lived. He was obliged to take 30 mg of prednisone to maintain platelet levels above 15-20 ϫ 10 9 /l. He was offered, and accepted, autologous SC transplantation, and underwent the procedure in March 1997. CD34 ϩ cells were obtained from the bone marrow. He received concentrated IgG, 0.4 g/kg ϫ5 days, in order to minimise blood loss after the multiple marrow aspirations, and his platelets rose to 8 ϫ 10 9 /l for 2 days. TCD was performed by positive selection utilising a Ceprate column (CellPro); data are shown in Table 1 .
Conditioning consisted of thiotepa, 10 mg/kg over 2 days, and CY, 150 mg/kg over 3 days. The clinical course was uneventful, but 11 platelet packs were required until 
Discussion
Eradication of an autoimmune disease utilising autologous SC, even if T cell depleted, has not been reported to date, and it is questionable whether this approach will ever prove successful. Even considering experimental results in which adjuvant irradiation to central and peripheral lymphoid tissue was given, 8 it is perhaps unrealistic to anticipate genuine tolerance to autoantigens after this procedure, the main mechanism of which clearly involves dose-related immunosuppression followed by autologous SC rescue. However, a consistent reduction in autoimmune potential has been found in other SADs such as multiple sclerosis 9 and autoimmune rheumatic diseases, 10 thus making the procedure an attractive option for very severe cases. However, AITP is a B cell, antibody-mediated autoimmune disease, and in refractory, constantly relapsing cases autologous SC transplantation, whether T cell depleted or not, may be less effective. For such cases, allogeneic SC, perhaps also derived from cord blood, following non-myeloablative, lymphoid-directed conditioning regimens, such as the combination of fludarabine-CY may become a realistic option in the near future.
